Company intelligence / Profile preview

Mission Right

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

Lead candidates MTX325 (USP30 inhibitor for Parkinson’s Disease, Phase II) and MTX652 (USP30 inhibitor for Heart Failure/HFpEF, Phase II). Several USP30 inhibitor programs in clinic or approaching development. Recent FDA approval for Phase II of MTX652 in Acute Kidney Injury and MHRA CTA for MTX325 in Parkinson’s.[1][3][4]

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Pfizer

Beyond the preview

Go deeper on Mission Right.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mission Right.

Explore the full profile